<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111010</article-id><article-id pub-id-type="publisher-id">ACM-39716</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_54662295.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血清胆红素指标异常与药物性肝损主要临床特征的关系
  The Associations between Abnormal Serum Bilirubin Levels and Clinical Characteristics of Drug-Induced Liver Damage
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>浩</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>硕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>秋月</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>璐</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>魏</surname><given-names>良洲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学院附属医院，消化内科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>69</fpage><lpage>77</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：分析血清胆红素指标异常与药物性肝损(Drug-induced liver injury, DILI)主要临床特征的关系。方法：收集自2013年3月至2019年3月期间在青岛大学医学院附属医院住院治疗的142例DILI患者为研究对象，按照血清胆红素水平分为胆红素正常组和胆红素异常组，比较病因、肝功能生化指标、病程恢复特点以及糖皮质激素(Glucocorticoid, GC)治疗选择倾向。结果：与血清胆红素指标正常的DILI患者相比，胆红素水平升高的DILI患者入院时血清肝功能生化指标基线水平较高，除γ-谷氨酰转肽酶(γ-glutamine transpeptidase, γ-GT)之外，差异有统计学意义(P &lt; 0.05)；住院治疗1周后谷草转氨酶(Aspartate aminotransferase, AST)下降速率较慢，总胆红素(Total bilirubin, TB)、间接胆红素(Indirect bilirubin, IB)及直接胆红素(Direct bilirubin, DB)下降速率较快，差异有统计学意义(P &lt; 0.05)。患者住院天数以及肝功能生化指标完全恢复的患者例数差异有统计学意义(P &lt; 0.05)。另外，血清胆红素水平升高的DILI患者治疗方案中应用GC的病例数较多；该组中应用GC的患者其血清肝酶基线水平明显高于未应用GC的患者，差异有统计学意义(P &lt; 0.05)；治疗1周后肝酶下降速率较快，差异有统计学意义(P &lt; 0.05)。结论：血清胆红素水平升高的DILI患者肝功能生化指标基线水平较高，治疗后AST恢复较慢，患者住院病程更长，治疗上更倾向于应用GC；在血清胆红素水平升高的DILI患者中，应用GC的患者血清肝酶基线水平较高，治疗后肝酶水平下降更显著。
    Objective: To analyze the associations between abnormal serum bilirubin levels and the clinical features of drug-induced liver injury (DILI). Methods: The clinical data of 142 DILI patients who were hospitalized in the Affiliated Hospital of Qingdao University Medical College were analyzed. According to the serum bilirubin levels, they were divided into normal bilirubin group and abnormal bilirubin group. The etiology, biochemical indicators of liver function, the characteristics of recovery, and selection of glucocorticoid (GC) treatment were compared. Results: Compared with DILI patients with normal serum bilirubin indexes, DILI patients with elevated bilirubin levels had a higher baseline level of serum biochemical indexes of liver function. The difference was statistically significant (P &lt; 0.05), except for γ-glutamine transpeptidase (γ-GT). After a week of treatment, serum aspartate aminotransferase (AST) levels declined at a slower speed, while the levels of total bilirubin (TB), indirect bilirubin (IB) and direct bilirubin (DB) declined at a faster speed. The differences were statistically significant (P &lt; 0.05). The differences in the length of stay and number of patients with full recovery of biochemical indicators of liver function were also statistically significant (P &lt; 0.05). Moreover, in the group of DILI patients with elevated serum bilirubin levels more subjects adopted GC treatment. In this group, the baseline levels of serum liver enzymes of patients who applied GC were significantly higher than those of patients who did not apply GC. The differences were statistically significant (P &lt; 0.05). After a week of treatment, the levels of liver enzymes in patients of this group decreased more rapidly. The differences were statistically significant (P &lt; 0.05). Conclusion: DILI patients with elevated serum bilirubin levels have a higher baseline level of biochemical indicators of liver function, a slower recovery of AST after treatment, and a longer hospital stay. Moreover, GC was more frequently used in treatment regimen. Among DILI patients with elevated serum bilirubin levels, patients who applied GC have higher baseline levels of serum liver enzymes, and a more significant decrease in liver enzyme levels after treatment. 
  
 
</p></abstract><kwd-group><kwd>DILI，胆红素，临床特征，GC, DILI</kwd><kwd> Bilirubin</kwd><kwd> Clinical Features</kwd><kwd> GC</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分析血清胆红素指标异常与药物性肝损(Drug-induced liver injury, DILI)主要临床特征的关系。方法：收集自2013年3月至2019年3月期间在青岛大学医学院附属医院住院治疗的142例DILI患者为研究对象，按照血清胆红素水平分为胆红素正常组和胆红素异常组，比较病因、肝功能生化指标、病程恢复特点以及糖皮质激素(Glucocorticoid, GC)治疗选择倾向。结果：与血清胆红素指标正常的DILI患者相比，胆红素水平升高的DILI患者入院时血清肝功能生化指标基线水平较高，除γ-谷氨酰转肽酶(γ-glutamine transpeptidase, γ-GT)之外，差异有统计学意义(P &lt; 0.05)；住院治疗1周后谷草转氨酶(Aspartate aminotransferase, AST)下降速率较慢，总胆红素(Total bilirubin, TB)、间接胆红素(Indirect bilirubin, IB)及直接胆红素(Direct bilirubin, DB)下降速率较快，差异有统计学意义(P &lt; 0.05)。患者住院天数以及肝功能生化指标完全恢复的患者例数差异有统计学意义(P &lt; 0.05)。另外，血清胆红素水平升高的DILI患者治疗方案中应用GC的病例数较多；该组中应用GC的患者其血清肝酶基线水平明显高于未应用GC的患者，差异有统计学意义(P &lt; 0.05)；治疗1周后肝酶下降速率较快，差异有统计学意义(P &lt; 0.05)。结论：血清胆红素水平升高的DILI患者肝功能生化指标基线水平较高，治疗后AST恢复较慢，患者住院病程更长，治疗上更倾向于应用GC；在血清胆红素水平升高的DILI患者中，应用GC的患者血清肝酶基线水平较高，治疗后肝酶水平下降更显著。</p></sec><sec id="s2"><title>关键词</title><p>DILI，胆红素，临床特征，GC</p></sec><sec id="s3"><title>The Associations between Abnormal Serum Bilirubin Levels and Clinical Characteristics of Drug-Induced Liver Damage</title><p>Hao Li, Shuo Zhang, Qiuyue Wang, Lu Feng, Liangzhou Wei<sup>*</sup></p><p>Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/10-1571807x5_hanspub.png" /></p><p>Received: Dec. 6<sup>th</sup>, 2020; accepted: Dec. 19<sup>th</sup>, 2020; published: Jan. 12<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/10-1571807x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To analyze the associations between abnormal serum bilirubin levels and the clinical features of drug-induced liver injury (DILI). Methods: The clinical data of 142 DILI patients who were hospitalized in the Affiliated Hospital of Qingdao University Medical College were analyzed. According to the serum bilirubin levels, they were divided into normal bilirubin group and abnormal bilirubin group. The etiology, biochemical indicators of liver function, the characteristics of recovery, and selection of glucocorticoid (GC) treatment were compared. Results: Compared with DILI patients with normal serum bilirubin indexes, DILI patients with elevated bilirubin levels had a higher baseline level of serum biochemical indexes of liver function. The difference was statistically significant (P &lt; 0.05), except for γ-glutamine transpeptidase (γ-GT). After a week of treatment, serum aspartate aminotransferase (AST) levels declined at a slower speed, while the levels of total bilirubin (TB), indirect bilirubin (IB) and direct bilirubin (DB) declined at a faster speed. The differences were statistically significant (P &lt; 0.05). The differences in the length of stay and number of patients with full recovery of biochemical indicators of liver function were also statistically significant (P &lt; 0.05). Moreover, in the group of DILI patients with elevated serum bilirubin levels more subjects adopted GC treatment. In this group, the baseline levels of serum liver enzymes of patients who applied GC were significantly higher than those of patients who did not apply GC. The differences were statistically significant (P &lt; 0.05). After a week of treatment, the levels of liver enzymes in patients of this group decreased more rapidly. The differences were statistically significant (P &lt; 0.05). Conclusion: DILI patients with elevated serum bilirubin levels have a higher baseline level of biochemical indicators of liver function, a slower recovery of AST after treatment, and a longer hospital stay. Moreover, GC was more frequently used in treatment regimen. Among DILI patients with elevated serum bilirubin levels, patients who applied GC have higher baseline levels of serum liver enzymes, and a more significant decrease in liver enzyme levels after treatment.</p><p>Keywords:DILI, Bilirubin, Clinical Features, GC</p><disp-formula id="hanspub.39716-formula2"><graphic xlink:href="//html.hanspub.org/file/10-1571807x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/10-1571807x8_hanspub.png" /> <img src="//html.hanspub.org/file/10-1571807x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>药物性肝损(Drug-induced liver injury, DILI)患者在消化专科住院治疗的患者中常见，其主要表现为肝内酶系统及胆红素系统等指标异常，伴有或不伴有纳差、厌油、乏力等临床表现。DILI主要是由化学药物、中草药、生物制剂及其代谢产物等对肝脏引起的损伤所致 [<xref ref-type="bibr" rid="hanspub.39716-ref1">1</xref>]。迄今仍缺乏简便、客观、特异的诊断指标及统一的严重程度分级系统。临床上用于判断DILI严重程度、临床特征以及恢复情况的方法，主要包括血液肝功能生化检验、影像学以及肝组织穿刺活检等。鉴于是否方便可靠、所在医疗机构的客观条件，以及患者意愿等多种原因，抽取静脉血检测肝功能生化指标仍然是目前各级医疗机构最广泛采用的手段。然而，这些肝功能生化指标的不同变化特征，对病程恢复特点有无提示意义，目前尚未确定。DILI患者的治疗手段主要是药物治疗，其目的为减少炎症活性因子产生、修复肝细胞损伤、改善肝细胞代谢，以及改善和促进胆红素处理和排泄系统功能等。根据中华医学会肝病学分会发布的《药物性肝损伤诊治指南》 [<xref ref-type="bibr" rid="hanspub.39716-ref2">2</xref>]，有较高的循证医学证据支持应用异甘草酸镁治疗肝细胞型DILI，应用熊去氧胆酸(Ursodeoxycholic acid, UDCA)治疗胆汁淤积型DILI。然而，糖皮质激素(Glucocorticoid, GC)对于DILI的疗效缺乏随机对照研究，GC剂量、疗程等尚无指南推荐意见。本文收集了2013~2019年142例因DILI住院治疗的患者，总结分析了血清胆红素指标异常与DILI患者主要临床特征的关系，并初步探讨了血清肝功能生化指标中伴有胆红素指标异常对应用GC治疗及肝功能指标恢复程度等是否具有提示意义，希望为DILI临床治疗提供一些参考。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>选取2013-03-01至2019-03-01期间在青岛大学医学院附属医院住院治疗的142例DILI患者为研究对象，诊断符合《药物性肝损伤诊治指南(2017年版)》的相关标准，排除既往病毒性肝炎、酒精性肝病、脂肪肝、肝囊肿等其他肝脏疾病患者、胆囊炎、胆囊结石患者及伴有心、脑、肾、肺等严重脏器疾病、造血系统疾病及肿瘤患者。</p></sec><sec id="s6_2"><title>2.2. 观察指标</title><p>包括：1) 患者入院时、入院治疗1周后肝功能生化指标，包括血清谷草转氨酶(Aspartate aminotransferase, AST)、谷丙转氨酶(Alanine transaminase, ALT)、碱性磷酸酶(Alkaline phosphatase, ALP)、γ-谷氨酰转肽酶(γ-glutamine transpeptidase, γ-GT)、总胆红素(Total bilirubin, TB)、直接胆红素(Direct bilirubin, DB)和间接胆红素(Indirect bilirubin, IB)水平；2) 各项肝功能生化指标恢复至正常水平的病例数；3) 患者住院天数；4) 应用GC的患者病例数。</p></sec><sec id="s6_3"><title>2.3. 研究方法</title><p>142例患者入院后均停用伤肝药物，并给予静脉滴注2400 mg还原性谷胱甘肽及150 mg异甘草酸镁治疗，每天1次。在此基础上，部分患者联合GC，具体方案：注射用甲泼尼龙琥珀酸钠，剂量为40 mg，静滴5~7天，后改为甲泼尼龙40 mg口服，用药剂量逐渐递减；或者予以醋酸泼尼松，剂量为40 mg，口服5~7天，后用药剂量逐渐递减。治疗期间患者加用胃黏膜保护剂及钙片。本研究实验室检查项目正常值范围采用青岛大学医学院附属医院实验室检查所用标准：ALT 7~40 U/L，AST 13~35 U/L，ALP 35~100 U/LL，γ-GT 7~45 U/L，TB 3.0~22.0 mmoI/L，DB 0~8.0 mmol/L。</p></sec><sec id="s6_4"><title>2.4. 病人分组</title><p>依据美国食品药品监督管理局定义“肝细胞性黄疸”中的生化肝功能值定义本研究中血清胆红素异常标准：ALT ≥ 3ULN + TB ≥ 2ULN [<xref ref-type="bibr" rid="hanspub.39716-ref3">3</xref>]。将纳入的DILI患者分为血清胆红素正常组和异常组；并根据是否应用GC治疗将胆红素异常组分为GC治疗组和未使用GC治疗组两个亚组，分别分析比较病因差异、肝酶基线水平、肝功能恢复病程特点及保肝药应用策略等临床特征。</p></sec><sec id="s6_5"><title>2.5. 统计学处理</title><p>数据采用SPSS 21.0软件进行统计分析。符合正态分布的计量资料以 x &#177; s 表示，两组间比较采用独立样本t检验；计数资料以百分比表示，采用卡方检验，统计学差异有意义的标准为P &lt; 0.05。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 一般资料</title><p>142例DILI患者中，血清胆红素指标异常组77例，胆红素指标正常组65例。其中胆红素异常组中男26例，女51例，年龄范围为24~74岁，胆红素正常组男20例，女45例，年龄范围为22~82岁。两组患者年龄、性别比较差异无统计学意义(P &gt; 0.05；表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Demographic characteristics of DILI patient</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >胆红素正常组(n = 65)</th><th align="center" valign="middle" >胆红素异常组(n = 77)</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >性别(男/女，例)</td><td align="center" valign="middle" >20/45</td><td align="center" valign="middle" >26/51</td><td align="center" valign="middle" >0.72</td></tr><tr><td align="center" valign="middle" >年龄( x &#175; &#177; s ，岁)</td><td align="center" valign="middle" >55.5 &#177; 13.2</td><td align="center" valign="middle" >51.4 &#177; 12.6</td><td align="center" valign="middle" >0.06</td></tr></tbody></table></table-wrap><p>表1. DILI患者人口学特征</p></sec><sec id="s7_2"><title>3.2. 引起DILI的药物分类及构成比</title><p>在两组患者中，引起DILI的药物种类较多，各类药物所占比例如表2所示。两组患者的病因比较中，中药、中成药和保健品在两组中所占比例远超其他药物，分别为26例(40.0%)和32 (41.6%)。其次多药联用、抗微生物药物、心脑血管药物、抗肿瘤药物在各组所占比例也相对较高。两组患者的诱发药物比例无显著统计学差异(P &gt; 0.05；表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Types of drugs inducing DIL</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >诱发药物</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >胆红素正常组百分比(%)</th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >胆红素异常组百分比(%)</th><th align="center" valign="middle" >p值</th></tr></thead><tr><td align="center" valign="middle" >中药&#183;中成药&#183;保健品</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >40.0</td><td align="center" valign="middle" >32</td><td align="center" valign="middle" >41.6</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >抗微生物药物</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >7.7</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >7.8</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >抗肿瘤药</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >4.6</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >5.2</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >免疫抑制剂</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3.1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.9</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >心脑血管药物</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >5.2</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >抗结核药物</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.5</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.6</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >非甾体类抗炎药</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3.1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.9</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >抗癫痫药</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.5</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.6</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >抗过敏药物</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >4.6</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >5.2</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >抗甲状腺药</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3.1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.6</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >降糖药</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3.1</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3.9</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >多药联用</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >15.</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >10.4</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >6.2</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >5.2</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >77</td><td align="center" valign="middle" >100</td><td align="center" valign="middle" >&gt; 0.05</td></tr></tbody></table></table-wrap><p>表2. 导致DILI的药物种类</p></sec><sec id="s7_3"><title>3.3. 入院肝功生化基线特征</title><p>血清胆红素升高组患者入院时，血清肝功能生化指标中ALT、AST、ALP水平明显高于胆红素正常组，差异有统计学意义(P &lt; 0.05)。两组患者的血清γ-GT水平无显著差别(P &gt; 0.05) (表3)。上述结果提示伴有血清胆红素异常的DILI患者肝功能损伤更为严重。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Baseline characteristics of biochemical indicators of liver functions in normal bilirubin group and abnormal bilirubin grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >ALT x &#175; &#177; S , U/L</th><th align="center" valign="middle" >AST x &#175; &#177; S , U/L</th><th align="center" valign="middle" >γ-GT x &#175; &#177; S , U/L</th><th align="center" valign="middle" >ALP x &#175; &#177; S , U/L</th><th align="center" valign="middle" >IB x &#175; &#177; S , &#181;mol/l</th><th align="center" valign="middle" >DB x &#175; &#177; S , &#181;mol/l</th><th align="center" valign="middle" >TB x &#175; &#177; S , &#181;mol/l</th></tr></thead><tr><td align="center" valign="middle" >胆红素正常组(n = 65)</td><td align="center" valign="middle" >394.98 &#177; 235.41</td><td align="center" valign="middle" >156.63 &#177; 87.21</td><td align="center" valign="middle" >171.38 &#177; 166.81</td><td align="center" valign="middle" >117.14 &#177; 108.21</td><td align="center" valign="middle" >7.43 &#177; 4.63</td><td align="center" valign="middle" >11.40 &#177; 4.24</td><td align="center" valign="middle" >18.71 &#177; 7.27</td></tr><tr><td align="center" valign="middle" >胆红素异常组(n = 77)</td><td align="center" valign="middle" >674.48 &#177; 486.78</td><td align="center" valign="middle" >332.41 &#177; 262.04</td><td align="center" valign="middle" >200.64 &#177; 196.67</td><td align="center" valign="middle" >158.36 &#177; 109.41</td><td align="center" valign="middle" >113.45 &#177; 8.28</td><td align="center" valign="middle" >52.66 &#177; 35.31</td><td align="center" valign="middle" >165.42 &#177; 111.97</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.01</td></tr></tbody></table></table-wrap><p>表3. 胆红素正常组与胆红素异常组肝功能生化指标基线特征</p></sec><sec id="s7_4"><title>3.4. DILI患者治疗前后肝功生化指标变化</title><p>在住院治疗1周后，血清胆红素正常组DILI患者AST水平下降百分比明显高于胆红素异常组，差异有统计学意义(P &lt; 0.05)，而ALT、γ-GT、ALP水平下降百分比与胆红素异常组无显著差别(P &gt; 0.05；表4)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Percentage decrease of biochemical indicators of liver function in normal bilirubin group and abnormal bilirubin group after a week of treatmen</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >ALT x &#175; &#177; S , U/L</th><th align="center" valign="middle" >AST x &#175; &#177; S , U/L</th><th align="center" valign="middle" >γ-GT x &#175; &#177; S , U/L</th><th align="center" valign="middle" >ALP x &#175; &#177; S , U/L</th><th align="center" valign="middle" >IB x &#175; &#177; S , &#181;mol/l</th><th align="center" valign="middle" >DB x &#175; &#177; S , &#181;mol/l</th><th align="center" valign="middle" >TB x &#175; &#177; S , &#181;mol/l</th></tr></thead><tr><td align="center" valign="middle" >胆红素正常组(n = 65)</td><td align="center" valign="middle" >56.37 &#177; 15.40</td><td align="center" valign="middle" >60.90 &#177; 17.14</td><td align="center" valign="middle" >21.40 &#177; 15.24</td><td align="center" valign="middle" >14.32 &#177; 11.12</td><td align="center" valign="middle" >27.98 &#177; 13.72</td><td align="center" valign="middle" >22.94 &#177; 16.27</td><td align="center" valign="middle" >23.72 &#177; 14.07</td></tr><tr><td align="center" valign="middle" >胆红素异常组(n = 77)</td><td align="center" valign="middle" >51.80 &#177; 17.39</td><td align="center" valign="middle" >46.67 &#177; 20.05</td><td align="center" valign="middle" >25.99 &#177; 14.34</td><td align="center" valign="middle" >17.09 &#177; 12.05</td><td align="center" valign="middle" >36.30 &#177; 19.34</td><td align="center" valign="middle" >39.06 &#177; 19.61</td><td align="center" valign="middle" >36.77 &#177; 19.37</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.01</td></tr></tbody></table></table-wrap><p>表4. 胆红素正常组与胆红素异常组治疗1周后肝功能生化指标下降百分比(%)</p></sec><sec id="s7_5"><title>3.5. DILI患者住院时间及出院时肝功能生化指标完全恢复比例</title><p>统计142例DILI患者住院病程天数，血清胆红素异常组患者平均住院时间为15.59 &#177; 3.92天(8~28天)，胆红素正常组患者住院时间为10.87 &#177; 3.31天(6~25天)，差异有统计学意义(P &lt; 0.05)。另外，血清胆红素异常组DILI患者出院时各项肝功能生化指标完全恢复的例数较少，差异有统计学意义(P &lt; 0.05；表5)，提示胆红素异常的DILI患者住院治疗期间，肝功能生化指标恢复正常更为困难。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Number of patients with fully recovery of biochemical indicators of liver functio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >ALT</th><th align="center" valign="middle" >AST</th><th align="center" valign="middle" >g-GT</th><th align="center" valign="middle" >ALP</th></tr></thead><tr><td align="center" valign="middle" >胆红素正常组(n = 65)</td><td align="center" valign="middle" >56 (86.15%)</td><td align="center" valign="middle" >39 (60.0%)</td><td align="center" valign="middle" >55 (84.62%)</td><td align="center" valign="middle" >44 (67.69%)</td></tr><tr><td align="center" valign="middle" >胆红素异常组(n = 77)</td><td align="center" valign="middle" >54 (70.13%)</td><td align="center" valign="middle" >30 (38.96%)</td><td align="center" valign="middle" >44 (57.14%)</td><td align="center" valign="middle" >34 (44.16%)</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.05</td></tr></tbody></table></table-wrap><p>表5. 肝功能生化指标完全恢复例数(n, %)</p></sec><sec id="s7_6"><title>3.6. 应用GC治疗情况</title><p>血清胆红素异常组DILI患者中有12例(15.58%)应用GC治疗，明显高于胆红素正常组(1例，1.54%)。从统计分析结果可以看出，血清胆红素异常组中应用GC治疗的DILI患者入院时多项肝功生化指标的基线水平较高，除γ-GT、ALP外，差异有统计学意义(P &lt; 0.05；表6)；住院治疗1周后肝功能生化指标(ALT, AST, γ-GT, ALP)下降百分比明显高于未使用GC治疗的DILI患者(NG)，差异有统计学意义(P &lt; 0.05；表7)。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Comparison of baseline levels of biochemical indicators of liver function in GC group and NG grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >ALT x &#175; &#177; S , U/L</th><th align="center" valign="middle" >AST x &#175; &#177; S , U/L</th><th align="center" valign="middle" >γ-GT x &#175; &#177; S , U/L</th><th align="center" valign="middle" >ALP x &#175; &#177; S , U/L</th><th align="center" valign="middle" >IB x &#175; &#177; S , &#181;mol/l</th><th align="center" valign="middle" >DB x &#175; &#177; S , &#181;mol/l</th><th align="center" valign="middle" >TB x &#175; &#177; S , &#181;mol/l</th></tr></thead><tr><td align="center" valign="middle" >GC组</td><td align="center" valign="middle" >1215.73 &#177; 740.15</td><td align="center" valign="middle" >513.80 &#177; 279.38</td><td align="center" valign="middle" >280.67 &#177; 261.95</td><td align="center" valign="middle" >164.09 &#177; 69.7</td><td align="center" valign="middle" >224.63 &#177; 56.78</td><td align="center" valign="middle" >83.12 &#177; 26.96</td><td align="center" valign="middle" >305.01 &#177; 63.23</td></tr><tr><td align="center" valign="middle" >NG组</td><td align="center" valign="middle" >574.55 &#177; 349.51</td><td align="center" valign="middle" >298.93 &#177; 246.61</td><td align="center" valign="middle" >177.70 &#177; 175.91</td><td align="center" valign="middle" >148.04 &#177; 82.75</td><td align="center" valign="middle" >92.32 &#177; 66.97</td><td align="center" valign="middle" >46.61 &#177; 33.78</td><td align="center" valign="middle" >138.93 &#177; 98.63</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.01</td></tr></tbody></table></table-wrap><p>表6. GC组与NG组肝功能生化指标基线水平比较</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> The percentage decrease of biochemical indicators of liver function in GC group and NG group after 1 week of treatment in DILI patients with elevated bilirubin level</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >ALT x &#175; &#177; S , U/L</th><th align="center" valign="middle" >AST x &#175; &#177; S , U/L</th><th align="center" valign="middle" >γ-GT x &#175; &#177; S , U/L</th><th align="center" valign="middle" >ALP x &#175; &#177; S , U/L</th><th align="center" valign="middle" >IB x &#175; &#177; S , &#181;mol/l</th><th align="center" valign="middle" >DB x &#175; &#177; S , &#181;mol/l</th><th align="center" valign="middle" >TB x &#175; &#177; S , &#181;mol/l</th></tr></thead><tr><td align="center" valign="middle" >GC组</td><td align="center" valign="middle" >66.42 &#177; 13.05</td><td align="center" valign="middle" >66.57 &#177; 16.58</td><td align="center" valign="middle" >50.81 &#177; 15.28</td><td align="center" valign="middle" >30.89 &#177; 15.89</td><td align="center" valign="middle" >44.24 &#177; 15.12</td><td align="center" valign="middle" >43.37 &#177; 24.58</td><td align="center" valign="middle" >44.90 &#177; 16.01</td></tr><tr><td align="center" valign="middle" >NG组</td><td align="center" valign="middle" >48.75 &#177; 16.43</td><td align="center" valign="middle" >49.26 &#177; 21.96</td><td align="center" valign="middle" >23.49 &#177; 19.84</td><td align="center" valign="middle" >16.78 &#177; 13.50</td><td align="center" valign="middle" >32.32 &#177; 18.89</td><td align="center" valign="middle" >36.02 &#177; 22.87</td><td align="center" valign="middle" >33.90 &#177; 18.72</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.01</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&lt;0.05</td></tr></tbody></table></table-wrap><p>表7. 血清胆红素升高DILI患者中GC组与NG组治疗1周后肝功能生化指标下降百分比(%)</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>肝脏接受和处置消化道来源的物质，参与转化、排泄全身的代谢产物或机体经由各种途径摄入的药物等化学成分，对物质的转化、代谢和解毒作用主要依赖肝细胞的生物酶体系，肝脏自身的解毒后排泄功能依赖胆汁的分泌和排泄。随着新药的不断研发并在临床中广泛应用，DILI发病率呈逐年上升趋势。在临床中，肝功能损伤是可逆的，但若不及时进行有效治疗和干预，肝功能衰竭终末期是其最终的不良转归。急性、慢性肝衰竭均具有较高的短期死亡率 [<xref ref-type="bibr" rid="hanspub.39716-ref4">4</xref>]。据统计，20%~40%的急性肝衰竭是由DILI引起的。对于DILI患者来说，目前临床尚无特异性的血清学标志物。血清肝功能生化检查包括：肝细胞酶类和胆红素系统的生化指标，它们是最实用的肝功能评价参数 [<xref ref-type="bibr" rid="hanspub.39716-ref5">5</xref>]。胆红素指标包括DB和IB，两者之和为TB。IB主要来源于红细胞破坏后血红蛋白的降解产物，在肝细胞内与葡萄糖醛酸结合形成DB，DB经胆管排泄于肠道，在肠道细菌作用下生成尿胆素原和尿胆原，绝大部分随粪便排出。约20%的尿胆原经肝肠循环重新转变为DB，在此过程中极少量尿胆原从尿中排出。胆红素的代谢过程相对复杂，涉及肝实质细胞及胆管的协同作用，包括对血液内胆红素的摄取、在肝细胞内的转运、IB转化为DB、DB经胆汁排泄等一系列紧密衔接且相互影响的生理过程 [<xref ref-type="bibr" rid="hanspub.39716-ref6">6</xref>]。因此胆红素较为全面地体现了肝功能的状态。基于受损靶细胞类型，DILI可分型为：肝细胞损伤型、胆汁淤积型、混合型，其中胆汁淤积型及混合型往往合并胆红素生化指标异常，大量胆红素储存在肝细胞内，特别是间接胆红素的沉积，可抑制UDP-葡萄糖醛酸转移酶和肝微粒体酶等酶的活性，从而进一步加重胆红素的代谢及排泄障碍，引起胆汁淤积。而长时间的淤胆可以引起肝内结构紊乱、微循环障碍、肝细胞变性，最终可导致肝细胞严重受损及不同程度的肝纤维化。因此血清胆红素指标异常的DILI患者往往有肝衰竭的倾向，预后较差，临床治疗上会需要提前干预或者更进一步的治疗 [<xref ref-type="bibr" rid="hanspub.39716-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.39716-ref8">8</xref>]。因此进一步了解肝细胞酶学和胆红素系统的改变对DILI治疗药物选择策略的提示作用，乃至对肝功能损伤病程特点的影响，能够提升肝功能生化检查在DILI肝功能损伤诊治中的参考价值。</p><p>本研究表明，血清胆红素指标异常的DILI患者与胆红素水平正常的DILI患者相比，诱发因素无明显差别。我们还发现，血清胆红素指标异常的DILI患者入院时，肝功能损伤程度更重，表现为血清肝功能生化指标中ALT、AST、ALP水平明显高于胆红素正常的DILI患者。入院治疗1周后，血清胆红素水平升高的DILI患者AST水平下降速率明显低于血清胆红素正常的DILI组。另外，血清胆红素异常的DILI患者住院病程更长，而且出院时各项肝功能生化指标完全恢复的例数更少。在药物应用方面，血清胆红素异常的DILI患者在应用常规保肝药的同时，更倾向于应用GC治疗。在血清胆红素指标异常的DILI患者中，应用GC的患者入院时往往表现为更严重的肝功能损伤，肝酶及胆红素系统生化指标均较高，治疗后肝酶水平下降较未用GC治疗者更为显著。</p><p>据全国308家医院的流行病学调查结果显示，各类药物引起DILI的比例是不一致的，在我国引起 DILI的常见药物多为中草药、抗结核药以及化疗药物。本研究中，血清胆红素指标异常的DILI患者与胆红素水平正常的DILI患者相比，诱发药物的种类及比例相似，提示其诱因无明显差别。两组患者导致DILI的药物最常见的是中药(包括中成药)，分别占40.0%和41.6%，其次为：抗微生物药、抗肿瘤药、心脑血管药等，与文献基本一致。在最新DILI患者的研究报告中 [<xref ref-type="bibr" rid="hanspub.39716-ref9">9</xref>]，以肝细胞损伤型(51.39%)占比最高，其次是混合性型(28.30%)和胆汁淤积型(20.31%)，但未统计各个分型中诱发药物比例，而本研究以胆红素是否异常分组，经统计分析发现两组患者的诱发药物比例无显著统计学差异。这可能与DILI发病机制有关，临床中常用的药物如：非甾体抗炎药、抗微生物药物、心脑血管药物等，其诱发肝损伤机制往往均涉及线粒体功能障碍、氧化应激、免疫反应等，不同类型的药物引起肝功能损伤类型往往会有重叠交叉 [<xref ref-type="bibr" rid="hanspub.39716-ref10">10</xref>]。而中药由于其成分复杂且其体内药代动力学研究相对匮乏，所以在DILI发病中的作用尚未完全阐明。近期也有研究发现，许多中药提取物及其化学成分可通过强效抑制尿苷二磷酸葡萄糖醛酸转移酶1A1 (UGT1A1)引发西药–中草药相互作用从而间接引起肝酶或胆红素指标异常 [<xref ref-type="bibr" rid="hanspub.39716-ref11">11</xref>]。</p><p>目前DILI诊断缺乏特异性指标，临床中主要以ALT、AST、AL、γ-GT、TB、IB等指标来进行DILI的早期诊断。ALT主要存在于细胞质，AST主要位于线粒体。当肝细胞受损时，ALT和AST会释放入血，尤其是严重肝细胞损伤时，导致线粒体内AST释放，AST/ALT比值升高，多提示预后不良 [<xref ref-type="bibr" rid="hanspub.39716-ref12">12</xref>]。ALP、γ-GT升高往往提示胆汁淤积，当胆管发生病变时，ALP和γ-GT生成增加而排泄减少，引起血清ALP、γ-GT升高。病变累及肝实质细胞时ALP也会轻度升高。胆红素的代谢过程涉及肝实质细胞及胆管系统协同作用。因此在临床中，肝酶系统指标及胆红素系统指标同时升高往往提示肝功能更差，预后不良。本研究结果表明，较单纯肝酶系统损伤的DILI患者来说，伴有血清胆红素水平升高的DILI患者，入院时肝酶指标基线水平较高，其肝功能损伤程度更重，肝酶指标恢复病程更长，导致整个住院时间延长，出院时肝功能指标完全恢复的患者较单纯肝酶系统异常的患者人数少。</p><p>DILI的治疗也相对复杂，首先应权衡利弊后决定是否停用可疑导致肝损药物，再根据DILI的临床类型选用适当的药物治疗，DILI诊治指南 [<xref ref-type="bibr" rid="hanspub.39716-ref2">2</xref>] 指出，对于ALT/AST升高的肝细胞型或混合型DILI可应用异甘草酸镁，轻中度肝细胞损伤型和混合型DILI可试用双环醇和甘草酸制剂，胆汁淤积型DILI可选用UDCA。然而，GC对于DILI的疗效缺乏随机对照研究。本研究中，血清胆红素异常组DILI患者中有12例应用GC治疗，明显高于胆红素正常组(1例)；而且在血清胆红素异常组DILI患者中，使用GC治疗的DILI患者在入院时AST、ALT等多项肝功生化指标的基线水平高，住院治疗1周后肝功能生化指标(ALT, AST, γ-GT, ALP)下降百分比明显高于未使用GC治疗的DILI患者。上述结果提示，GC对于胆红素指标异常的DILI患者的治疗可能是有益的。机体的免疫功能亢进、内毒素血症等因素均为DILI发病原因 [<xref ref-type="bibr" rid="hanspub.39716-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.39716-ref14">14</xref>]。GC可以与细胞内GC受体(Glucocorticoid receptor, GR)结合，促进GR与胞核内特异性DNA位点结合后调控靶基因转录，从而发挥抗炎、抗休克、调节胆汁酸代谢及免疫抑制等功效 [<xref ref-type="bibr" rid="hanspub.39716-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.39716-ref16">16</xref>]。因此对于DILI患者，GC能减轻肝细胞的免疫性损伤而改善症状。有研究表明：在血清胆红素异常的肝功能损伤患者的治疗中，GC主要通过诱导BEP蛋白表达，将具有多选择性的有机阴离子转运至胆汁中，通过离子转运机制间接降低胆红素水平 [<xref ref-type="bibr" rid="hanspub.39716-ref17">17</xref>]。虽然具体机制目前仍不清晰，但在临床实践中，GC已用于大多数肝病如酒精性肝炎、自身免疫性肝炎、胆汁淤积性肝炎等的治疗中 [<xref ref-type="bibr" rid="hanspub.39716-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.39716-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.39716-ref20">20</xref>]。由于GC对血清胆红素异常DILI患者的疗效、用药的时机及方式未形成共识，加之长期应用后可能会出现各种并发症，后续仍需进行大范围随机对照临床研究，为更规范有效地使用GC治疗DILI提供更准确有力的证据。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，与血清胆红素水平正常的DILI患者相比，胆红素水平升高的DILI患者入院时肝功能生化指标基线水平较高，治疗后肝酶水平恢复较慢，患者住院病程更长。治疗上在应用常规保肝药的基础上，更倾向于应用GC；在血清胆红素水平升高的DILI患者中，应用GC的患者血清肝酶基线水平较高，治疗后肝酶水平下降更显著，提示应用GC治疗可以提高临床治疗效果，改善患者的预后。本研究通过回顾性分析相关临床治疗资料，获得相应的伦理许可，为伴有血清胆红素水平升高的DILI患者的临床治疗提供了资料。然而该研究也存在很多局限性，包括样本量小，资料来源于单中心(人群覆盖范围有地域性局限，用药习惯可能不具广泛代表性。在治疗过程中未完全按照治疗指南治疗)等，以后尚需设计周密的前瞻性、多中心临床研究。</p></sec><sec id="s10"><title>文章引用</title><p>李 浩,张 硕,王秋月,冯 璐,魏良洲. 血清胆红素指标异常与药物性肝损主要临床特征的关系The Associations between Abnormal Serum Bilirubin Levels and Clinical Characteristics of Drug-Induced Liver Damage[J]. 临床医学进展, 2021, 11(01): 69-77. https://doi.org/10.12677/ACM.2021.111010</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39716-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Isaacson, M. and Babich, M. (2020) Drug-Induced Liver Injury Resources and Reporting for the Clinician. Clinics in Liver Disease, 24, 131-139. &lt;br&gt;https://doi.org/10.1016/j.cld.2019.09.010</mixed-citation></ref><ref id="hanspub.39716-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Yu, Y.C., Mao, Y.M, Chen, C.W., Chen, J.-J., Chen, J., Cong, W.-M., et al. (2017) CSH Guidelines for the Diagnosis and Treatment of Drug-Induced Liver Injury. Hepatology International, 11, 221-241.  
&lt;br&gt;https://doi.org/10.1007/s12072-017-9793-2</mixed-citation></ref><ref id="hanspub.39716-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Chalasani, N.P., Hayashi, P.H., Bonkovsky, H.L., Navarro, V.J., Lee, W.M., Fontana, R.J., et al. (2014) ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug Induced Liver Injury. American Journal of Gastroenterology, 109, 950-966. &lt;br&gt;https://doi.org/10.1038/ajg.2014.131</mixed-citation></ref><ref id="hanspub.39716-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Woreta, T.A. and Alqahtani, S.A. (2014) Evaluation of Abnormal Liver Tests. Medical Clinics of North America, 98, 1-16. &lt;br&gt;https://doi.org/10.1016/j.mcna.2013.09.005</mixed-citation></ref><ref id="hanspub.39716-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Yu, Y.C., Mao, Y.M., Chen, C.W., et al. (2017) CSH Guidelines for the Diagnosis and Treatment of Drug-Induced Liver Injury. Hepatology International, 11, 221-241.</mixed-citation></ref><ref id="hanspub.39716-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Hoekstra, L.T., De Graaf, W., Nibourg, G.A.A., Heger, M., Bennink, R.J., Stieger, B., et al. (2013) Physiological and Biochemical Basis of Clinical Liver Function Tests. Annals of Surgery, 257, 27-36.  
&lt;br&gt;https://doi.org/10.1097/SLA.0b013e31825d5d47</mixed-citation></ref><ref id="hanspub.39716-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sullivan, J.I. and Rockey, D.C. (2017) Diagnosis and Evaluation of Hyperbilirubinemia. Current Opinion in Gastroenterology, 33, 164-170. &lt;br&gt;https://doi.org/10.1097/MOG.0000000000000354</mixed-citation></ref><ref id="hanspub.39716-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Olson, J.C. (2016) Acute-on-Chronic and Decompensated Chronic Liver Failure: Definitions, Epidemiology, and Prognostication. Critical Care Clinics, 32, 301-309. &lt;br&gt;https://doi.org/10.1016/j.ccc.2016.02.001</mixed-citation></ref><ref id="hanspub.39716-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Shen, T., Liu, Y.X., Shang, J., Xie, Q., Li, J., Yan, M., et al. (2019) Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. Gastroenterology, 156, 2230-2241. &lt;br&gt;https://doi.org/10.1053/j.gastro.2019.02.002</mixed-citation></ref><ref id="hanspub.39716-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Joseph, J.A. and Odin, J.A. (2017) Epidemiology and Genetic Risk Factors of Drug Hepatotoxicity. Clinics in Liver Disease, 21, 55-72. &lt;br&gt;https://doi.org/10.1016/j.cld.2016.08.004</mixed-citation></ref><ref id="hanspub.39716-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Oda, S., Fukami, T., Yokoi, T. and Nakajima, M. (2015) A Comprehensive Review of UDP-Glucuronosyltransferase and Esterases for Drug Development. Drug Metabolism and Pharmacokinetics, 30, 30-51. 
&lt;br&gt;https://doi.org/10.1016/j.dmpk.2014.12.001</mixed-citation></ref><ref id="hanspub.39716-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Misdraji, J. (2010) Embryology, Anatomy, Histology, and Developmental Anomalies of the Liver. In: Feldman, M., Friedman, L.S. and Brandt, L.J., Eds., Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, Elsevier, Amsterdam, 1129-1134.</mixed-citation></ref><ref id="hanspub.39716-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Fontana, R.J. (2014) Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives. Gastroenterology, 146, 914-928.E1. &lt;br&gt;https://doi.org/10.1053/j.gastro.2013.12.032</mixed-citation></ref><ref id="hanspub.39716-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Itai, C., Hettick, J.M. and Siegel, P.D. (2011) Haptenation: Chemical Reactivity and Protein Binding. Journal of Allergy, 2011, Article ID: 839682. &lt;br&gt;https://doi.org/10.1155/2011/839682</mixed-citation></ref><ref id="hanspub.39716-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Buttgereit, F., Spies, C.M. and Bijlsma, J.W.J. (2015) Novel Glucocorticoids: Where Are We Now and Where Do We Want to Go? Clinical &amp; Experimental Rheumatology, 33, 29-33.</mixed-citation></ref><ref id="hanspub.39716-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Adcock, I.M. and Mumby, S. (2016) Glucocorticoids. In: Page, C. and Barnes, P., Eds., Pharmacology and Therapeutics of Asthma and COPD, Handbook of Experimental Pharmacology, Vol. 237, Springer, Cham, 171-196.  
&lt;br&gt;https://doi.org/10.1007/164_2016_98</mixed-citation></ref><ref id="hanspub.39716-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W. and Gluud, C. (2004) Glucocorticosteroids for Primary Sclerosing Cholangitis. Cochrane Database of Systematic Reviews, 3, Article No. CD004036. &lt;br&gt;https://doi.org/10.1002/14651858.CD004036.pub2</mixed-citation></ref><ref id="hanspub.39716-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Pavlov, C.S., Varganova, D.L., Casazza, G., Tsochatzis, E., Nikolova, D. and Gluud, C. (2017) Glucocorticosteroids for People with Alcoholic Hepatitis. Cochrane Database of Systematic Reviews, 2017, Article No. CD001511. 
&lt;br&gt;https://doi.org/10.1002/14651858.CD001511.pub3</mixed-citation></ref><ref id="hanspub.39716-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">金超, 潘洁露, 喻晓, 等. 自身免疫性肝炎临床治疗进展[J]. 临床肝胆病杂志, 2019, 35(10).</mixed-citation></ref><ref id="hanspub.39716-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 胆汁淤积性肝病诊断和治疗共识[J]. 肝脏, 2015, 35(1): 39-51.</mixed-citation></ref></ref-list></back></article>